CANNABIS SCIENCE Co-Sponsors The 38th Annual Conference Of The National Organization For The Reform Of Marijuana Laws (NORML) Conference On Legalization Of Cannabis

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, reports on the recent 38th Annual Conference of the National Organization for the Reform of Marijuana Laws (NORML) held in San Francisco, CA., which was co-sponsored by Cannabis Science Inc.

The first day of the conference was dedicated to the subject of the medical use of cannabis, and speakers reported new discoveries concerning its medical use. Polls consistently show that an overwhelming majority of Americans support patients being allowed access to cannabis.

Richard Cowan, Cannabis Science Inc., CFO and former Executive Director of NORML also moderated a panel of distinguished speakers who addressed the problems in Mexico caused by marijuana prohibition. Cowan began by reporting on his presentation to a Conference in Mexico City on Cannabis policy sponsored by the Mexican Congress on April 15, 2009. CBIS reported on his speech in a press release.

The NORML Conference panel moderated by Cowan included Norm Stamper, Ph.D., who spoke on behalf of Law Enforcement Against Prohibition (LEAP.cc) Stamper was a police officer for 34 years, and served as chief of the Seattle Police Department from 1994 to 2000. His speech emphasized that there is growing opposition to marijuana prohibition even among law enforcement.

Cannabis Science CEO, Dr. Robert Melamede, said, "We thought it appropriate to co-sponsor the NORML conference to demonstrate that our business model is not predicated on a continuation of marijuana prohibition, and we believe that there will be a need for FDA approved cannabis-based medicines, available either by prescription or over-the-counter, whether or not marijuana prohibition ends. Also, we wanted to emphasize again that we are a patient oriented company."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.